Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CANbridge Files to Start China Trials of Esophageal Cancer Treatment

publication date: Dec 21, 2017

CANbridge Life Sciences, a Beijing biopharma, filed an IND application to the CFDA for a Phase Ib/III trial of CAN017 in esophageal squamous cell cancer (ESCC). Founded in 2012, CANbridge develops western drugs for China and North Asia. The company in-licensed rights to CAN017 in 2016 from Aveo Oncology of Massachusetts in a $134 million agreement. The IND is CANbridge’s second CFDA submission in 2017; it filed an IND for its lead candidate, CAN008, for glioblastoma, in July. More details....

Stock Symbol: (NSDQ: AVEO)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital